Inerma, UAB

Company age: 12 y. 2 mo.

Update

Company overview

Company name Inerma, UAB
Company code 303340790
VAT code LT100008689410
Registered address Vilnius, Čiobiškio g. 6-69, LT-07181
Registration date 2014-07-01 Company age: 12 y. 2 mo.
Phone Phone
Email Not disclosed (personal)
Company manager For registered members only Log in
Revenue (2025) 41,000 € -4% History
Profit (2025) -13,906 € History
Share capital 2,896 €
Number of employees 2 History
Managed vehicles 0
Current SODRA debt No debt Read more
Days of debt to SODRA per year 10 days
Current VMI debt 788 € From: 2025-11-28 Read more
Financial statements All submitted
Legal form Private Limited Liability Company
NACE activity Retail sale of pharmaceutical products
Ownership form Private without foreign capital
Viešųjų pardavimų suma pask. 12 mėn 528 € List

Download a detailed company report

Make confident decisions with all the information about Inerma, UAB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.

19.99 € + PVM Get report

Description

This description was generated by artificial intelligence.
Inerma, UAB (company code 303340790) is an operational private limited liability company registered in 2014. It is a privately owned Lithuanian company with a CEO-only governance structure and is classified as a micro business in the sector of national private non-financial companies. The company operates in retail sale of pharmaceutical products (EVRK G.47.73.00). Its registered address is in Vilnius, Ciobiškio g. 6-69, Vilniaus m. sav., Vilniaus apskr.

The company reported revenue of EUR 41.0K in 2025, slightly below the previous year, while still above the 2023 level. It remained loss-making, with net loss of EUR 13.9K in 2025, an improvement from EUR 16.3K in 2024 and EUR 23.8K in 2023. At the end of 2025, equity was negative at EUR 88.1K, liabilities stood at EUR 172.5K, and total assets were EUR 84.4K. The company had 3 average employees in 2023, 2024 and 2025, and 2 average employees so far in 2026, indicating a decline in staffing.